论文部分内容阅读
指南推荐对于行经皮冠状动脉介入治疗(PCI)药物支架置入的患者应行术后双联抗血小板治疗(dual anti-platelet therapy,DAT)至少1年,用于改善近期、远期预后,同时预防支架内血栓形成。然而合并糖尿病的冠心病患者因为血小板的高活力状态,相对非糖尿病患者,在DAT治疗下仍残留较高的死亡、缺血和支架内血栓形成的风险。如何针对合并糖尿病的冠心病人群加以合理的抗血小板治疗成为研究热点与难点,本文将结合该问题的临床研究进展加以综述。
Guidelines recommend that patients undergoing percutaneous coronary intervention (PCI) stent placement be treated with postoperative dual anti-platelet therapy (DAT) for at least 1 year to improve near-term and long-term prognosis, Prevention of stent thrombosis. However, patients with coronary heart disease complicated with diabetes still have a higher risk of death, ischemia and stent thrombosis under DAT treatment due to the platelet hypervolemia compared with non-diabetic patients. How to treat diabetic coronary heart disease with reasonable antiplatelet therapy has become a research hotspot and difficulty, this article will be combined with the progress of clinical research on the issue to be reviewed.